Zealand Pharma A/S (22Z.F)
| Previous close | 29.94 |
| Open | 30.38 |
| Bid | 29.38 x 60000 |
| Ask | 30.26 x 60000 |
| Day's range | 30.38 - 30.38 |
| 52-week range | 9.57 - 32.06 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 1.605B |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.88 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 222.65 |
- GlobeNewswire
Zealand Pharma Provides Update on Silicon Valley Bank Closure
Company announcement – No. 6 / 2023 Zealand Pharma Provides Update on Silicon Valley Bank Closure Update to company announcement No.5 following joint statement by U.S. Treasury, Federal Reserve, and FDIC: Depositors at SVB will have access to all of their money starting Monday, March 13Zealand now expects to recover all of its deposits held at SVB, Monday March 13 Copenhagen, Denmark March 13, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the disc
- GlobeNewswire
Zealand Pharma Provides Statement on Silicon Valley Bank Closure
Company announcement – No. 5 / 2023 Zealand Pharma Provides Statement on Silicon Valley Bank Closure Copenhagen, Denmark March 12, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today issued the following statement: On March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank (SVB) and appointed the Federal Deposit Insurance Corpor
- GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 4 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 10, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securitie
